Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Hematol. 2002 Jul;9(4):345-52.

TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches.

Author information

  • 1Department of Pediatric Hematology-Oncology, University of California-San Francisco, San Francisco, California 94143-0519, USA. lohm@itsa.ucsf.edu

Abstract

This article presents the most recent insights into the biology, prognostic significance, and therapeutic approaches to TEL/AML1-positive leukemia. The TEL/AML1 fusion gene, also known as ETV6 /CBFA2, is the most commonly occurring gene rearrangement in pediatric acute lymphoblastic leukemia (ALL). Considerable controversy exists over its prognostic significance with currently available therapies. Differences in outcome may be explained by the differing intensities of various chemotherapy regimens, individual host responses to chemotherapy, or the hypothesis that relapsed TEL/AML1-positive leukemia represents an outgrowth of a secondary leukemia that shares a common initiating event with the first. Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome.

PMID:
12042710
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center